The performance of Biotech stocks thus far this month is nothing to write home about, if we were to look at it from the standpoint of the movement of the NYSE Arca Biotechnology Index. A peek at what transpired on the FDA front in August and a preview of what September holds in store for us look pertinent.
from RTT - Biotech http://ift.tt/2caVSMc
via IFTTT
No comments:
Post a Comment